Pfizer has raised its full-year profit guidance as its cost-cutting efforts build steam and US President Donald Trump pushes drugmakers to slash their prices.
The US pharmaceutical group on Tuesday raised its guidance for adjusted earnings per share by 10 cents to a range of between $2.90 to $3.10.
The new guidance includes a one-time cost associated with Pfizer’s licensing deal with Chinese biotech 3SBio announced earlier this year.
您已閱讀25%（435字），剩余75%（1325字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。